Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H trial of the GCLLSG)

被引：11

作者：

Stilgenbauer, Stephan ^{[1
]}

Winkler, Dirk ^{[1
]}

Buehler, Andreas ^{[1
]}

Zenz, Thorsten ^{[1
]}

Groner, Sija ^{[1
]}

Busch, Raymonde ^{[1
]}

Hensel, Manfred ^{[1
]}

Duehrsen, Uhich ^{[1
]}

Finke, Juergen ^{[1
]}

Dreger, Peter ^{[1
]}

Jaeger, Ulrich ^{[1
]}

Lengfelder, Eva ^{[1
]}

Truemper, Lorenz ^{[1
]}

Soeling, Ulrike ^{[1
]}

Schlag, Rudolf ^{[1
]}

Hallek, Michael ^{[1
]}

Doehner, Hartmut ^{[1
]}

机构：

[1] Univ Ulm, D-89069 Ulm, Germany

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.3120.3120

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3120

引用

页码：918A / 918A

页数：1

共 50 条

[1] Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers
Stilgenbauer, Stephan
Zenz, Thorsten
Winkler, Dirk
Buehler, Andreas
Groner, Sija
Busch, Raymonde
Hensel, Manfred
Duehrsen, Ulrich
Finke, Juergen
Dreger, Peter
Jaeger, Ulrich
Lengfelder, Eva
Truemper, Lorenz H.
Soeling, Ulrike
Schlag, Rudolf
Hallek, Michael
Doehner, Hartmut
BLOOD, 2008, 112 (11) : 127 - 127
[2] Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2h study of the German CLL study group (GCLLSG).
Stilgenbauer, S
Winkler, D
Kröber, A
Kienle, D
Hallek, M
Hensel, M
Lengfelder, E
Trümper, L
Dreger, P
Jäger, U
Döhner, H
BLOOD, 2004, 104 (11) : 140A - 140A
[3] Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL:: CLL2H study of the German CLL Study Group (GCLLSG)
Stilgenbauer, S
Kröber, A
Winkler, D
Kienle, D
Busch, R
Hallek, M
Hensel, M
Lengfelder, E
Trümper, L
Dreger, P
Jäger, U
Döhner, H
ANNALS OF ONCOLOGY, 2005, 16 : 43 - 43
[4] High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial
Bloehdorn, Johannes
Sill, Martin
Langer, Christian
Benner, Axel
Zenz, Thorsten
Buehler, Andreas
Busch, Raymonde
Dreger, Peter
Jaeger, Ulrich
Hallek, Michael
Doehner, Hartmut
Stilgenbauer, Stephan
BLOOD, 2013, 122 (21)
[5] ALEMTUZUMAB IN FLUDARABINE-REFRACTORY CLL
Ionita, H.
Cheveresan, L.
Ionita, I.
Cheveresan, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 604 - 604
[6] P53 independent activity of subcutaneous MabCampath® in fludarabine-refractory CLL
Stilgenbauer, S
ANNALS OF ONCOLOGY, 2005, 16 : 256 - 256
[7] NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG
Schnaiter, Andrea
Paschka, Peter
Rossi, Marianna
Zenz, Thorsten
Buehler, Andreas
Winkler, Dirk
Cazzola, Mario
Doehner, Konstanze
Edelmann, Jennifer
Mertens, Daniel
Kless, Sabrina
Mack, Silja
Busch, Raymonde
Hallek, Michael
Doehner, Hartmut
Stilgenbauer, Stephan
BLOOD, 2013, 122 (07) : 1266 - 1270
[8] NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg
Schnaiter, Andrea
Rossi, Marianna
Paschka, Peter
Cazzola, Mario
Doehner, Konstanze
Edelmann, Jennifer
Buehler, Andreas
Kless, Sabrina
Mertens, Daniel
Busch, Raymonde
Mack, Silja
Hallek, Michael
Doehner, Hartmut
Stilgenbauer, Stephan
BLOOD, 2012, 120 (21)
[9] The activity of alemtuzumab is independent of P53 mutational status in fludarabine refractory CLL:: Final analysis from the CLL2H study of the GCLLSG
Zenz, T.
Haebe, S.
Denzel, T.
Winkler, D.
Hallek, M.
Hensel, M.
Lengfelder, E.
Dreger, P.
Jaeger, U.
Doehner, H.
Stilgenbauer, S.
ANNALS OF ONCOLOGY, 2008, 19 : 193 - 194
[10] The activity of alemtuzumab is independent of p53 mutational status in fludarabine refractory CLL:: Interim analysis from the CLL2H study of the GCLLSG
Zenz, T.
Haebe, S.
Denzel, T.
Winkler, D.
Kroeber, A.
Kienle, D.
Hallek, M.
Hensel, M.
Lengfelder, E.
Truemper, L.
Dreger, P.
Jaeger, U.
Doehner, H.
Stilgenbauer, S.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 42 - 42

← 1 2 3 4 5 →